{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:36:48Z","timestamp":1758040608315,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.amjmed.2019.10.027","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T23:04:53Z","timestamp":1573254293000},"page":"e183-e186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist"],"prefix":"10.1016","volume":"133","author":[{"given":"Michael","family":"Boxer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Biuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2019.10.027_bib0001","doi-asserted-by":"crossref","unstructured":"PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364:1305-1314.","DOI":"10.1056\/NEJMoa1014475"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0002","doi-asserted-by":"crossref","unstructured":"Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139:271-278.","DOI":"10.1378\/chest.10-2243"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0003","doi-asserted-by":"crossref","unstructured":"Williamson DR, Lesur O, Tetrault JP, Nault V, Pilon D. Thrombocytopenia in the critically ill: prevalence, incidence, risk factors, and clinical outcomes. Can J Anaesth. 2013;60:641-651.","DOI":"10.1007\/s12630-013-9933-7"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0004","doi-asserted-by":"crossref","unstructured":"Wang TY, Ou FS, Roe MT, et al. Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. Circulation. 2009;119:2454-2462.","DOI":"10.1161\/CIRCULATIONAHA.108.827162"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0005","doi-asserted-by":"crossref","unstructured":"Arnold DM, Lim W.A rational approach to the diagnosis and management of thrombocytopenia in the hospitalized patient. Semin Hematol. 2011;48:251-258.","DOI":"10.1053\/j.seminhematol.2011.08.002"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0006","doi-asserted-by":"crossref","unstructured":"Ali N, Auerbach HE.New-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approach. J Community Hosp Intern Med Perspect. 2017;7:157-167.","DOI":"10.1080\/20009666.2017.1335156"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0007","doi-asserted-by":"crossref","unstructured":"Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39-50.","DOI":"10.2147\/HMER.S74612"},{"key":"10.1016\/j.amjmed.2019.10.027_bib0008","doi-asserted-by":"crossref","unstructured":"Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-alpha production in vivo. Blood. 2006;107:637-641.","DOI":"10.1182\/blood-2005-06-2202"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319309702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934319309702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:20:17Z","timestamp":1757582417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934319309702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0002934319309702"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.10.027","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Etiologies of Thrombocytopenia in the Community Hospital: The Experience of 1 Hematologist","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2019.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}